Psychemedics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Psychemedics ha un patrimonio netto totale di $5.4M e un debito totale di $495.0K, che porta il suo rapporto debito/patrimonio netto a 9.1%. Le sue attività totali e le sue passività totali sono rispettivamente $9.8M e $4.4M.

Informazioni chiave

9.1%

Rapporto debito/patrimonio netto

US$495.00k

Debito

Indice di copertura degli interessi	n/a
Contanti	US$1.41m
Patrimonio netto	US$5.45m
Totale passività	US$4.39m
Totale attività	US$9.84m

Aggiornamenti recenti sulla salute finanziaria

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05

Recent updates

Psychemedics Corporation's (NASDAQ:PMD) Shares Climb 37% But Its Business Is Yet to Catch Up

Dec 07

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Jul 29

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Jan 08

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

May 13

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Aug 09

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Apr 25

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Nov 18

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Oct 18

Psychemedics reports Q1 results

May 10

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

May 07

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Jan 30

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

Jan 11

Psychemedics reports Q3 results

Nov 09

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $6.0M ) di PMDI superano le sue passività a breve termine ( $3.8M ).

Passività a lungo termine: Le attività a breve termine di PMDI ( $6.0M ) superano le sue passività a lungo termine ( $596.0K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: PMDI ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di PMDI è aumentato da 7.3% a 9.1% negli ultimi 5 anni.

Copertura del debito: Il debito di PMDI è ben coperto dal flusso di cassa operativo ( 115.6% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di PMDI siano ben coperti dall'EBIT.

Psychemedics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Recent updates

Psychemedics Corporation(OTCPK:PMDI) dropped from S&P TMI Index

Psychemedics Corporation(OTCPK:PMDI) dropped from NASDAQ Composite Index

Psychemedics Corporation's (NASDAQ:PMD) Shares Climb 37% But Its Business Is Yet to Catch Up

New minor risk - Share price stability

Third quarter 2024 earnings released: US$0.091 loss per share (vs US$0.36 loss in 3Q 2023)

Psychemedics Corporation, Annual General Meeting, Nov 25, 2024

Psychemedics Corporation Launches New Ketamine Hair Testing Service

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.13 loss in 2Q 2023)

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New minor risk - Share price stability

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New major risk - Market cap size

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.068 loss in 1Q 2023)

Full year 2023 earnings released: US$0.72 loss per share (vs US$0.19 loss in FY 2022)

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.017 loss in 3Q 2022)

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.06 loss in 2Q 2022)

New minor risk - Shareholder dilution

Psychemedics Corporation, Annual General Meeting, Aug 17, 2023

Psychemedics Corporation Announces Board Changes

Upcoming dividend of US$0.07 per share at 5.6% yield

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.007 profit in 1Q 2022)

Psychemedics Corporation Declares Cash Dividend, Payable on June 8, 2023

Full year 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in FY 2021)

Psychemedics Corporation Appoints William Norris as Controller of the Company, Effective as of January 1, 2023

Upcoming dividend of US$0.07 per share

Third quarter 2022 earnings released: US$0.017 loss per share (vs US$0.13 profit in 3Q 2021)

Third quarter 2022 earnings released: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)

Psychemedics Corporation Declares Quarterly Cash Dividend, Payable on December 16, 2022

Psychemedics Corporation Announces Executive Changes

Upcoming dividend of US$0.07 per share

Second quarter 2022 earnings released: US$0.06 loss per share (vs US$0.024 profit in 2Q 2021)

Psychemedics Corporation Announces Quarterly Dividend, Payable on September 9, 2022

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics Corporation, Annual General Meeting, Aug 12, 2022

Upcoming dividend of US$0.07 per share

First quarter 2022 earnings: EPS exceeds analyst expectations

Psychemedics Corporation Declares Cash Dividend for First Quarter Ended March 31, 2022, Payable on June 24, 2022

Insider recently bought US$268k worth of stock

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Insider recently bought US$268k worth of stock

Insider recently bought US$112k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Insider recently bought US$393k worth of stock

Psychemedics Corporation Enters into Binding Memorandum of Understanding to Settle Purported Class Action Lawsuit Against It Related to Certain California Wage and Hour Laws

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.20 loss in 3Q 2020)

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Insider recently bought US$76k worth of stock

Insider recently bought US$728k worth of stock

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.37 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.029 loss in 1Q 2020)

Psychemedics reports Q1 results

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

Full year 2020 earnings released: US$0.70 loss per share (vs US$0.28 profit in FY 2019)

Psychemedics Corporation Elects Robyn C. Davis on the Board of Director, Effective Immediately

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

New 90-day high: US$7.45

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

New 90-day high: US$5.36

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

New 90-day high: US$5.14

Insider recently bought US$258k worth of stock

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel